Rhythm Operating Cycle from 2010 to 2026

RYTM Stock  USD 108.36  2.41  2.27%   
Rhythm Pharmaceuticals Operating Cycle yearly trend continues to be very stable with very little volatility. Operating Cycle is likely to drop to 350.73. During the period from 2010 to 2026, Rhythm Pharmaceuticals Operating Cycle quarterly data regression pattern had sample variance of  22,367 and median of  186.26. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
507.27
Current Value
350.73
Quarterly Volatility
149.55551672
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Rhythm Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rhythm Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.3 M, Interest Expense of 11.9 M or Selling General Administrative of 174.2 M, as well as many indicators such as Price To Sales Ratio of 28.67, Dividend Yield of 9.0E-4 or PTB Ratio of 19.61. Rhythm financial statements analysis is a perfect complement when working with Rhythm Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Rhythm Stock
Check out the analysis of Rhythm Pharmaceuticals Correlation against competitors.
To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.

Latest Rhythm Pharmaceuticals' Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Rhythm Pharmaceuticals over the last few years. It is Rhythm Pharmaceuticals' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rhythm Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

Rhythm Operating Cycle Regression Statistics

Arithmetic Mean274.14
Geometric Mean245.42
Coefficient Of Variation54.55
Mean Deviation124.08
Median186.26
Standard Deviation149.56
Sample Variance22,367
Range409
R-Value0.71
Mean Square Error11,845
R-Squared0.50
Significance0
Slope21.02
Total Sum of Squares357,870

Rhythm Operating Cycle History

2026 350.73
2025 507.27
2024 563.63
2023 408.48
2022 595.26

About Rhythm Pharmaceuticals Financial Statements

Rhythm Pharmaceuticals investors utilize fundamental indicators, such as Operating Cycle, to predict how Rhythm Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Operating Cycle 507.27  350.73 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Rhythm Pharmaceuticals is a strong investment it is important to analyze Rhythm Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rhythm Pharmaceuticals' future performance. For an informed investment choice regarding Rhythm Stock, refer to the following important reports:
Check out the analysis of Rhythm Pharmaceuticals Correlation against competitors.
To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.10)
Revenue Per Share
2.739
Quarterly Revenue Growth
0.543
Return On Assets
(0.27)
Return On Equity
(0.86)
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.